Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2017, Article ID 6145651, 13 pages
https://doi.org/10.1155/2017/6145651
Research Article

The Effect of CM082, an Oral Tyrosine Kinase Inhibitor, on Experimental Choroidal Neovascularization in Rats

1Department of Ophthalmology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China
2Department of Cardiac Surgery, Institute of Cardiovascular Diseases of Fudan University, Affiliated Zhongshan Hospital of Fudan University, Shanghai, China
3DMPK & Bioanalysis Department Sundia MediTech Company, Shanghai, China
4Department of Ophthalmology, Shanghai Tenth People’s Hospital, Shanghai, China
5Department of First Clinical Medical College, Nanjing Medical University, Nanjing, China
6Department of Ophthalmology, Shanghai Tenth People’s Hospital, Nanchang University, Nanchang, China

Correspondence should be addressed to Jing Yu; moc.nuyila@gnijuyrd

Received 4 January 2017; Revised 3 April 2017; Accepted 27 August 2017; Published 22 October 2017

Academic Editor: Lisa Toto

Copyright © 2017 Chengda Ren et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Silvestri, M. A. Williams, C. McAuley et al., “Drusen prevalence and pigmentary changes in Caucasians aged 18–54 years,” Eye, vol. 26, no. 10, pp. 1357–1362, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. J. D. Stein, P. A. Newman-Casey, T. Mrinalini, P. P. Lee, and D. W. Hutton, “Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration,” Ophthalmology, vol. 121, no. 4, pp. 936–945, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. “Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration,” Klinische Monatsblatter fur Augenheilkunde, vol. 224, no. 7, pp. 559–566, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. L. P. Aiello, J. M. Northrup, B. A. Keyt, H. Takagi, and M. A. Iwamoto, “Hypoxic regulation of vascular endothelial growth factor in retinal cells,” Archives of Ophthalmology, vol. 113, no. 12, pp. 1538–1544, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Grisanti and O. Tatar, “The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration,” Progress in Retinal and Eye Research, vol. 27, no. 4, pp. 372–390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Hay and N. Sonenberg, “Upstream and downstream of mTOR,” Genes & Development, vol. 18, no. 16, pp. 1926–1945, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Watari, S. Nakao, A. Fotovati et al., “Role of macrophages in inflammatory lymphangiogenesis: enhanced production of vascular endothelial growth factor C and D through NF-κB activation,” Biochemical and Biophysical Research Communications, vol. 377, no. 3, pp. 826–831, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Djordjevic and P. C. Driscoll, “Targeting VEGF signalling via the neuropilin co-receptor,” Drug Discovery Today, vol. 18, no. 9-10, pp. 447–455, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. R. L. Sidman, J. Li, M. Lawrence et al., “The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease,” Science Translational Medicine, vol. 7, no. 309, article 309ra165, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Koch and L. Claesson-Welsh, “Signal transduction by vascular endothelial growth factor receptors,” Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 7, article a006502, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. V. S. Dedania and S. J. Bakri, “Current perspectives on ranibizumab,” Clinical Ophthalmology, vol. 9, pp. 533–542, 2015. View at Google Scholar
  12. J. S. Reis-Filho and A. N. Tutt, “Triple negative tumours: a critical review,” Histopathology, vol. 52, no. 1, pp. 108–118, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. D. M. Brown, J. S. Heier, T. Ciulla et al., “Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration,” Ophthalmology, vol. 118, no. 6, pp. 1089–1097, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. F. Bashshur, A. Bazarbachi, A. Schakal, Z. A. Haddad, C. P. El Haibi, and B. N. Noureddin, “Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration,” American Journal of Ophthalmology, vol. 142, no. 1, pp. 1–9, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. L. M. Ellis and D. J. Hicklin, “VEGF-targeted therapy: mechanisms of anti-tumour activity,” Nature Reviews Cancer, vol. 8, no. 8, pp. 579–591, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. G. J. Jaffe, D. F. Martin, C. A. Toth et al., “Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials,” Ophthalmology, vol. 120, no. 9, pp. 1860–1870, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Zehetner, R. Kirchmair, S. B. Neururer, M. T. Kralinger, N. E. Bechrakis, and G. F. Kieselbach, “Systemic upregulation of PDGF-B in patients with neovascular AMD,” Investigative Ophthalmology & Visual Science, vol. 55, no. 1, pp. 337–344, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. G. J. Jaffe, D. Eliott, J. A. Wells, J. L. Prenner, A. Papp, and S. Patel, “A phase 1 study of intravitreous E10030 in combination with ranibizumab in neovascular age-related macular degeneration,” Ophthalmology, vol. 123, no. 1, pp. 78–85, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Bergers, S. Song, N. Meyer-Morse, E. Bergsland, and D. Hanahan, “Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors,” The Journal of Clinical Investigation, vol. 111, no. 9, pp. 1287–1295, 2003. View at Publisher · View at Google Scholar
  21. C. Hellberg, A. Ostman, and C. H. Heldin, “PDGF and vessel maturation,” Recent Results in Cancer Research, vol. 180, pp. 103–114, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. P. E. Pecen and P. K. Kaiser, “Current phase 1/2 research for neovascular age-related macular degeneration,” Current Opinion in Ophthalmology, vol. 26, no. 3, pp. 188–193, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Takehana, T. Kurokawa, T. Kitamura et al., “Suppression of laser-induced choroidal neovascularization by oral tranilast in the rat,” Investigative Ophthalmology & Visual Science, vol. 40, no. 2, pp. 459–466, 1999. View at Google Scholar
  24. D. M. Brown, M. Michels, P. K. Kaiser et al., “Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study,” Ophthalmology, vol. 116, no. 1, pp. 57–65.e5, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Tufail, P. J. Patel, C. Egan et al., “Bevacizumab for neovascular age related macular degeneration (ABC trial): multicentre randomised double masked study,” British Medical Journal, vol. 340, article c2459, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. K. M. Sampat and S. J. Garg, “Complications of intravitreal injections,” Current Opinion in Ophthalmology, vol. 21, no. 3, pp. 178–183, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Lux, H. Llacer, F. M. Heussen, and A. M. Joussen, “Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions,” British Journal of Ophthalmology, vol. 91, no. 10, pp. 1318–1322, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Kiba, H. Sagara, T. Hara, and M. Shibuya, “VEGFR-2-specific ligand VEGF-E induces non-edematous hyper-vascularization in mice,” Biochemical and Biophysical Research Communications, vol. 301, no. 2, pp. 371–377, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. S. A. Stacker, C. Caesar, M. E. Baldwin et al., “VEGF-D promotes the metastatic spread of tumor cells via the lymphatics,” Nature Medicine, vol. 7, no. 2, pp. 186–191, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Erber, A. Thurnher, A. D. Katsen et al., “Combined inhibition of VEGF- and PDGF-signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms,” The FASEB Journal, vol. 18, no. 2, pp. 338–340, 2004. View at Publisher · View at Google Scholar
  31. H. Cakmak, K. Ergin, G. Bozkurt, T. Kocaturk, and G. E. Evlicoglu, “The effects of topical everolimus and sunitinib on corneal neovascularization,” Cutaneous and Ocular Toxicology, vol. 35, no. 2, pp. 97–103, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. P. K. Kaiser, “Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases,” American Journal of Ophthalmology, vol. 142, no. 4, pp. 660–668.e1, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Sonpavde, T. E. Hutson, and C. N. Sternberg, “Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma,” Expert Opinion on Investigational Drugs, vol. 17, no. 2, pp. 253–261, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. K. G. Csaky, P. U. Dugel, A. J. Pierce et al., “Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration,” Ophthalmology, vol. 122, no. 3, pp. 579–588, 2015. View at Google Scholar
  35. M. M. McLaughlin, M. G. Paglione, J. Slakter et al., “Initial exploration of oral pazopanib in healthy participants and patients with age-related macular degeneration,” JAMA Ophthalmology, vol. 131, no. 12, pp. 1595–1601, 2013. View at Publisher · View at Google Scholar · View at Scopus